FBLN1 loss, using siRNA mediated knockdown of FBLN1C and FBLN1D, in NSCLC Calu-1 cells significantly increased EGF mediated EGFR activation, inhibited EGFR activation, promoted EGFR-dependent cell migration that inhibited upon Erlotinib treatment. Here, FBLN1 is linked to non-small cell lung carcinoma.